BioCryst Pharmaceuticals BCRX Income taxes at U.S. statutory rate of 21%
Income taxes at U.S. statutory rate of 21% at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's income taxes at u.s. statutory rate of 21%.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's income taxes at U.S. statutory rate of 21%?
- BioCryst Pharmaceuticals (BCRX) reported income taxes at U.S. statutory rate of 21% of 21% in Q4 2025.
- How has BioCryst Pharmaceuticals's income taxes at U.S. statutory rate of 21% changed year-over-year?
- BioCryst Pharmaceuticals's income taxes at U.S. statutory rate of 21% decreased by 0.0% year-over-year, from 21% to 21%.
- What does income taxes at U.S. statutory rate of 21% mean?
- Represents the theoretical income tax expense calculated using the U.S. federal statutory rate applied to income before taxes. It acts as the primary benchmark for analyzing the company's tax efficiency and the impact of various tax adjustments.